Jacek Otlewski

Predicting the reactivity of proteins from their sequence alone: Kazal family of protein inhibitors of serine proteinases.

Amino-acid substitutions at the fully exposed P1 site of bovine pancreatic trypsin inhibitor affect its stability.

Analysis of serine proteinase-inhibitor interaction by alanine shaving.

Thermodynamics of single peptide bond cleavage in bovine pancreatic trypsin inhibitor (BPTI).

NMR structures of two variants of bovine pancreatic trypsin inhibitor (BPTI) reveal unexpected influence of mutations on protein structure and stability.

Hydrogen bonds in human ubiquitin reflected in temperature coefficients of amide protons.

Importance of alpha-helix N-capping motif in stabilization of betabetaalpha fold.

Amyloid-forming peptides selected proteolytically from phage display library.

PDZ domains - common players in the cell signaling.

Trypsin specificity as elucidated by LIE calculations, X-ray structures, and association constant measurements.

Design of fully active FGF-1 variants with increased stability.

Crystal structures of five bovine chymotrypsin complexes with P1 BPTI variants.

The many faces of protease-protein inhibitor interaction.

Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action.

The dimerization mechanism of LIS1 and its implication for proteins containing the LisH motif.

The molecular basis of RhoA specificity in the guanine nucleotide exchange factor PDZ-RhoGEF.

Crystal structure of Vigna radiata cytokinin-specific binding protein in complex with zeatin.

Novel peptide recognized by RhoA GTPase.

Structural requirements of FGF-1 for receptor binding and translocation into cells.

Bivalent peptides as models for multimeric targets of PDZ domains.

Expression, purification and crystallization of cysteine-rich human protein muskelin in Escherichia coli.

Degenerate specificity of PDZ domains from RhoA-specific nucleotide exchange factors PDZRhoGEF and LARG.

Dissecting the thermodynamics of GAP-RhoA interactions.

Structure of a highly stable mutant of human fibroblast growth factor 1.

Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.

The high Zn(II) affinity of the tetracysteine tag affects its fluorescent labeling with biarsenicals.

Longer action means better drug: tuning up protein therapeutics.

Design and characteristics of a stable protein scaffold for specific binding based on variable lymphocyte receptor sequences.

PDZ domain from Dishevelled -- a specificity study.

Tailoring small proteins towards biomedical applications.

Selection and characterization of human antibody fragments specific for psoriasin - a cancer associated protein.

Femtomolar Zn2+ affinity of LIM domain of PDLIM1 protein uncovers crucial contribution of protein-protein interactions to protein stability.

A novel, stable, helical scaffold as an alternative binder - construction of phage display libraries.

FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation.

Aptamers: molecules of great potential.

Protease resistant variants of FGF1 with prolonged biological activity.

Design, expression and characterization of a highly stable tetratricopeptide-based protein scaffold for phage display application.

Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles.

Nucleolin regulates phosphorylation and nuclear export of fibroblast growth factor 1 (FGF1).

Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells.

Current methods for the synthesis of homogeneous antibody-drug conjugates.

Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule.

Selection of specific interactors from phage display library based on sea lamprey variable lymphocyte receptor sequences.

Identification of new FGF1 binding partners-Implications for its intracellular function.

A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.

Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.

High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.

Site-specific conjugation of fibroblast growth factor 2 (FGF2) based on incorporation of alkyne-reactive unnatural amino acid.

High-Yield Site-Specific Conjugation of Fibroblast Growth Factor 1 with Monomethylauristatin E via Cysteine Flanked by Basic Residues.

The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding.

Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.

Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1.

Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation.

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401.

Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment.

Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection.

Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling.

Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.

Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity.

FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent manner.

Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions.

Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1).

FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization.

Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential.

FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1.